SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sight Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.26−0.02 (-0.24%)
Close on Oct 19, 2026
- Market cap
- $450.22M
- P/E (TTM)
- –
- Dividend yield
- –
Sight Sciences, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Glaucoma | $78.44M | $76.95M | $75.72M | $74.83M | $73.75M | $74.76M | $75.90M | $74.29M | $74.08M | $75.23M | $74.31M | $75.91M | 94.1% | +6.4% |
| Interventional Dry Eye | $4.94M | $2.60M | $1.64M | $1.22M | $2.56M | $3.35M | $3.96M | $5.26M | $5.32M | $6.26M | $6.75M | $6.94M | 5.9% | +93.3% |
By product or service
By region
From the segment and revenue-disaggregation notes of Sight Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.